Answer
Yes, Gazyvaro (obinutuzumab) is indicated for previously untreated advanced follicular lymphoma in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response.
Sources for this answer
- Gazyvaro 1,000 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 20Document updated
Sources checked